Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ:SHPH
Shuttle Pharmaceuticals — Investor Presentation (March 2024)
21 slides from Shuttle Pharmaceuticals's investor presentation, Mar 21, 2024
Slide 1: Shuttle Pharmaceuticals Holdings, Inc. Investor Presentation
Shuttle Pharmaceuticals Holdings, Inc. Nasdaq: SHPH Investor Presentation February 2024
Slide 2: Disclaimers
Disclaimers Forward Looking Statements All of the information contained within this business presentation (the “Presentation”) has been obtained from sources generally believed to be reliable by Shuttle Pharmaceuticals Holdings, Inc. (referred to herein as “Shuttle Pharmaceuticals,” “Shuttle Pharma”
Slide 3: Company Overview
Company Overview Shuttle Pharma (Nasdaq: SHPH) is a clinical-stage biopharma company developing next generation drugs and diagnostics designed to improve radiation therapy outcomes. Biopharma Therapeutics Mission is to improve the lives of cancer patients receiving Radiation Therapy (RT) by incr
Slide 4: BioPharma: Radiation Sensitizers
BioPharma: Radiation Sensitizers
Slide 5: The Fundamental Problem Facing Radiation Therapy
The Fundamental Problem Facing Radiation Therapy Cancers are resistant to cure by radiation therapy because tumors are surrounded by radiation sensitive normal tissues that limit the maximum treatment dose Strategies to overcome cancer resistance to radiation therapy: Sensitize Cancer Cells To Rad
Slide 6: Radiation Sensitizers: Pipeline
Radiation Sensitizers: Pipeline Pipeline composed of two parts: Ropidoxuridine is the lead clinical drug candidate for sensitizing rapidly growing cancer cells and, selective HDAC (histone deacetylase) inhibitors which stimulate the immune system to irradiated cancers. 6 Shuttle Pharmaceuticals Hold
Slide 7: Ropidoxuridine Platform: Clinical Studies
Ropidoxuridine Platform: Clinical Studies Ropidoxuridine (IPdR) is the prodrug of IUdR IUdR is a powerful radiation sensitizer showing Phase II efficacy in NIH sponsored clinical trials IUdR and RT improved survival for glioblastoma and anaplastic astrocytoma patients and for sarcoma patients
Slide 8: Recent Activities
Recent Activities Results of Pre-IND Meeting with the FDA – IND approved, safe to proceed letter received January 5, 2024 The FDA's positive feedback and guidance on the Company's Chemistry, Manufacturing, and Controls (CMC) and clinical protocol design for Ropidoxuridine provided a pathway for
Slide 9: HDAC Inhibitor Platform: Overview
HDAC Inhibitor Platform: Overview Shuttle Pharma has discovered novel HDAC inhibitors using proprietary technology. Cancer radiation sensitization, normal tissue protection and selective HDAC6 inhibition have been observed in preclinical model testing. Our HDAC inhibitors are undergoing pre-clin
Slide 10: Intellectual Property Portfolio for Radiation Sensitizers
Intellectual Property Portfolio for Radiation Sensitizers Intellectual property for Ropidoxuridine includes a novel formulation demonstrating improved drug bioavailability Our HDAC inhibitor intellectual property includes new patent applications and granted patents discovered/invented by Shuttle
Slide 11: Clinical Development Strategy for Radiation Sensitizers
Clinical Development Strategy for Radiation Sensitizers Shuttle Pharma has a broad pipeline to improve clinical outcomes of patients treated with radiation therapy for cancer Priority #1: Clinical development of Ropidoxuridine & RT Capitalize on Ropidoxuridine as an orally available, small mol
Slide 12: Diagnostics: Predictive Biomarkers
Diagnostics: Predictive Biomarkers
Slide 13: Diagnostics: Market Opportunity
Diagnostics: Market Opportunity Predictive biomarkers for prostate cancers #2 ~ 268,000 new prostate cancer cases annually in the U.S. (incidence) ~ 3,100,000 patients currently live with prostate cancer in the U.S. (prevalence) ~ 66,000 patients with localized radiation (30%) receive RT for
Slide 14: Diagnostics: Competitive Landscape
Diagnostics: Competitive Landscape #2 ~1.8M ~900,000 ~50,000 14 Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH)
Slide 15: Diagnostics: Product Development
Diagnostics: Product Development Calibrants for standard vials/ metabolomics and lipidomics QC and internal standards NIST Plasma reference standard User Manual Guide USB Stick with proprietary software to calculate score index 2 x 96 well plate for sample preparation Pre-formatted mat
Slide 16: Diagnostics: Clinical Development
Diagnostics: Clinical Development 1. Establish and validate the predictive assay by performing a muti-institutional clinical trial for assay validation in the context of use (COU) for FDA approval. 360 patient multi-institutional validation clinical trial. Blood drawn prior to standard of care r
Slide 17: Intellectual Property Portfolio for Diagnostics
Intellectual Property Portfolio for Diagnostics Diagnostic predictive biomarker patent application includes Georgetown University faculty and Shuttle Pharma scientists as co-inventors and has been filed by Georgetown University. Shuttle Pharma has obtained an exclusive license for development and
Slide 18: Financials & Management
Financials & Management - 4 eo
Slide 19: Financial Overview
Financial Overview Shuttle Pharmaceuticals Capital Market Profile Cap Table as of September 30, 2023 Common Stock 15,999,125 Exchange/Ticker NASDAQ: SHPH Fully Vested Restricted Stock Units (RSUs) 90,549 Closing Stock Price* $0.35 RSUs Outstanding 168,050 52 Wk High/Low* $0.35 - $2.75 Warrants Outst
Slide 20: Shuttle's Experienced Leadership Team
Shuttle’s Experienced Leadership Team Founder & CEO of Shuttle Served as President Served as CFO of Pharma since 2012; Chairman, & COO of Shuttle Shuttle Pharma since Board of Directors 2017 Pharma since 2012 2019 Member, Board of Directors, MBA George MHSA George Neopharm Inc. 1990 Wash
Slide 21: Thank You
THANK YOU Shuttle Pharmaceuticals Holdings, Inc. Anatoly Dritschilo, MD, CEO Tel: (240) 403-1212 Email: anatoly.dritschilo@ShuttlePharma.org Investor Relations Lytham Partners Robert Blum Tel: (602) 889-9700 Email: SHPH@LythamPartners.com 21
Shuttle Pharmaceuticals Holdings — Investor Presentation (March 2024) on 6ix